A Phase 3, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

Trial Profile

A Phase 3, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Jun 2017

At a glance

  • Drugs Ivacaftor (Primary) ; Ivacaftor/lumacaftor (Primary) ; Lumacaftor (Primary)
  • Indications Cystic fibrosis
  • Focus Registrational; Therapeutic Use
  • Acronyms TRANSPORT
  • Sponsors Vertex Pharmaceuticals
  • Most Recent Events

    • 09 Jun 2017 According to a Vertex Pharmaceuticals media release, post-hoc analysis data from TRAFFIC, TRANSPORT and PROGRESS studies were presented at the 40th European Cystic Fibrosis Society (ECFS) Conference.
    • 08 Mar 2016 According to a Vertex Pharmaceuticals media release, the Therapeutic Goods Administration (TGA) of Australia approved ORKAMBI 200/125 (lumacaftor 200mg and ivacaftor 125mg), the first medicine to treat the underlying cause of cystic fibrosis (CF) in people ages 12 and older who have two copies of the F508del mutation.
    • 26 Jan 2016 According to a Vertex Pharmaceuticals media release, lumacaftor/ivacaftor (ORKAMBI) has been approved by Health Canada treat the underlying cause of cystic fibrosis (CF) in people ages 12 and older with two copies of the F508del mutation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top